Journal of Blood Medicine最新文献

{"title":"Thrombotic Thrombocytopenic Purpura and Evans Syndrome: Validating and Exploring 20 Years of Routine Hospital Care.","authors":"Dana Audrey Lawrie, Dennis Lund Hansen, Thomas Leineweber Kristensen, Sarah Birgitte Ingemod Sand Carlsen, Louise Hur Hannig, Per Trøllund Pedersen, Helene Bjørg Kristensen, Mads Okkels Birk Lorenzen, Jesper Stentoft, Peter Buur Van Kooten Niekerk, Maren Poulsgaard Jørgensen, Marianne Tang Severinsen, Mikkel Helleberg Dorff, Robert Schou Pedersen, Andreas Glenthøj, Henrik Frederiksen","doi":"10.2147/JBM.S513578","DOIUrl":"10.2147/JBM.S513578","url":null,"abstract":"<p><strong>Purpose: </strong>Few patients scattered among centers complicate investigation of thrombotic thrombocytopenic purpura (TTP) and Evans syndrome (ES). Routinely collected Danish register data captures the total population and includes lifelong follow-up. We aimed to validate registered TTP and ES diagnoses and to explore clinical characteristics.</p><p><strong>Patients and methods: </strong>We identified all patients in Denmark with diagnosis registrations indicative of TTP or ES in the Danish National Patient Registry 2000-2019, validated diagnoses through medical record review, and extracted and presented data on initial treatment and complications.</p><p><strong>Results: </strong>Diagnoses for patients registered with TTP and ES were confirmed for 46% and 59%, respectively. Among validated TTP patients the most widespread complications at time of diagnosis were neurological symptoms or deficits, observed in 81% of cases. Other frequent types of complications in TTP patients were any organ failure (32%) and infection (25%). Initial management and complications did not change for patients diagnosed between 2000 and 2009 and 2010 and 2019, and survival remained constant (overall mortality 26%, median follow up of 8.4 years). Treatments and complications also remained unchanged for ES patients.</p><p><strong>Conclusion: </strong>Overall, diagnostic accuracy, complications and prognosis have remained relatively constant for patients over the study period. These now validated cohorts of Danish TTP and ES patients will be utilized in future studies to examine long-term health outcomes.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"16 ","pages":"279-292"},"PeriodicalIF":2.1,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12153936/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transplantation of Human Peripheral Stem and Progenitor Cells to Humanized Mouse Model for Systemic Lupus Erythematosus.","authors":"Syahrul Chilmi, Dina Fauziah, Matthew Brian Khrisna, Ifa Fauziah, Friska Supriyanto, Kusworini Handono, Kevin Reinaldo Sunjaya, Wimardy Leonard Wijaya, Mustofa Aidid, Hani Susianti","doi":"10.2147/JBM.S499999","DOIUrl":"10.2147/JBM.S499999","url":null,"abstract":"<p><strong>Introduction: </strong>Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by damaged and dysregulated immune system due to breakdown in the selection process during clonal growth of immune cells. Studies have shown that patients with systemic lupus erythematosus (SLE) display altered gene expression patterns and increased double-stranded DNA breaks within their hematopoietic stem and progenitor cells (HSPC). However, the current animal models for SLE found in the existing literature predominantly emphasize the use of peripheral blood mononuclear cells (PBMC) over HSPC for the creation of humanized mouse models. Nevertheless, these prior models were constrained by the limited efficiency of human cell engraftment and limited PBMC ability to replicate the capacity of HSPC to generate human SLE cells that can engraft host mice, thus making the transplant protocol inadequate.</p><p><strong>Patients and methods: </strong>Transplantation was initiated by extracting HSPC from stable SLE patients by leukapheresis. The collected cells were assessed for purity before storage at -80 °C. Humanized mice were conditioned with cyclophosphamide and total-body irradiation before receiving the HSPC transplant. After transplantation, the mice were administered human granulocyte-colony stimulating factor and sacrificed to evaluate autoantibodies and HSPC in their bone marrow and blood samples. Statistical analysis was performed using Student's <i>t</i>-test and one-way ANOVA.</p><p><strong>Results: </strong>Upon human stem cells engravement into mice, we found a noteworthy presence of HSPC, as evidenced by the positive expression of hCD45, hCD34, and/or hCD44, and the production of human antinuclear antibodies. The results indicated that the transplanted mice generated reactive autoantibodies against human cells, similar to that observed in the human donor patient. These findings shed light on the survival and behavior of transplanted human stem cells in a mouse model.</p><p><strong>Conclusion: </strong>In this study, we successfully induced immunodeficiency in mice for xenotransplantation with human peripheral stem cells.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"16 ","pages":"269-277"},"PeriodicalIF":2.1,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12145791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144248001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aplastic Anaemia Disease Burden From the Patient Perspective and Quality of Life in Zimbabwe by A. <i>Maramba and J. Mupini</i>.","authors":"Aaron Maramba, Joice Mupini, Shungu Munyati, Tendai Chris Maboreke, Justen Manasa, Lovemore Gwanzura","doi":"10.2147/JBM.S457128","DOIUrl":"10.2147/JBM.S457128","url":null,"abstract":"<p><strong>Purpose: </strong>Aplastic Anaemia (AA) is a critical haematological disorder characterized by pancytopenia and marrow hypoplasia. It is generally regarded as a rare disease albeit with multiple symptoms. The aim of the study was to get the patients' perspective to evaluate the disease burden and their knowledge, attitude, practices, and adherence to treatment.</p><p><strong>Patients and methods: </strong>This qualitative cross-sectional study was conducted at the Parirenyatwa Group of Hospitals in Harare, Zimbabwe, to investigate patients' perspectives on their knowledge, attitudes, practices and disease burden regarding AA.</p><p><strong>Results: </strong>Eleven participants diagnosed with AA via bone marrow biopsy were recruited between November 2022 and May 2023. A structured, ethically approved questionnaire was used to gather data on demographics, clinical status, treatment experiences, and overall disease knowledge. Results showed that respondents generally possessed a robust understanding of their condition; however, financial constraints significantly hindered access to appropriate treatment options, including potential curative therapies such as hematopoietic stem cell transplantation. Zimbabwean healthcare faces profound challenges, with less than 5% of patients receiving appropriate therapy within the first year of diagnosis.</p><p><strong>Conclusion: </strong>This study underscores the urgent need for enhanced patient support systems and policies to improve healthcare access for individuals with AA in Zimbabwe. Recommendations include the development of targeted awareness initiatives and supportive resources to elevate the quality of life for patients with aplastic anaemia.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"16 ","pages":"259-268"},"PeriodicalIF":2.1,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12134467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144225528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Evidence on Joint Condition in Non-Severe Hemophilia A Patients: A Multicenter Study.","authors":"Ana Marco-Rico, José Manuel Calvo-Villas, Francisco-José López-Jaime, Mariana Canaro Hirnyk, Maria Del Mar Nieto Hernández, Sonia Herrero Martín, Laura Entrena-Ureña, Shally Marcellini-Antonio, Bolívar L Díaz-Jordán, Sergio Jurado-Herrera, Noelia Florencia Pérez-González, Covadonga García-Díaz, Faustino García-Candel, Ihosvany Fernández-Bello, Pascual Marco-Vera","doi":"10.2147/JBM.S517596","DOIUrl":"10.2147/JBM.S517596","url":null,"abstract":"<p><strong>Purpose: </strong>Patients with non-severe hemophilia A (PwnSHA) may be at risk for joint damage (JD), yet data remain scarce. Our aim was to evaluate the joint condition in PwnSHA in a real-world setting.</p><p><strong>Patients and methods: </strong>A nationwide, multicenter, cross-sectional study was conducted. To mitigate the impact of discrepancies between factor VIII (FVIII) assays, baseline FVIII levels were determined using chromogenic and one-step clotting assays. Mutation in F8 gene, baseline FVIII levels, thrombin generation and age were assessed. The joint condition was described using the HEAD-US score by trained specialists at each participating hospital.</p><p><strong>Results: </strong>One hundred and twenty-four patients were recruited, 84 of them with an available HEAD-US evaluation, who were finally included in our analysis. The median age was 38.4 years (18.3-48.5). Twenty percent (16/84) had moderate hemophilia (MoH) with FVIII levels of 4.0 IU/dL (2.6-4.6), and 80% (68/84) had mild hemophilia (MiH) with FVIII levels of 14.8 IU/dL (10.4-19.9), (p< 0.001). JD (HEAD-US>0) was observed in 50% (8/16) of MoH patients (HEAD-US= 6.5 [5.5-8.5]) and in 40% (27/68) of those with MiH (HEAD-US= 3.0 [2.0-6.5]), p=0.198. In the moderate group, JD was primarily observed in ankles (44%), while in the MiH group, knees were the most affected (31%). MoH patients reported a hypocoagulable thrombin generation profile compared to MiH patients (p<0.05).</p><p><strong>Conclusion: </strong>Near half of PwnSHA had JD. A worse joint health and a lower thrombin generation was observed in MoH population. These patients can benefit from an early prophylaxis and prevent further joint deterioration. Future research should explore additional variables that might influence joint condition.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"16 ","pages":"251-258"},"PeriodicalIF":2.1,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12101468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alpha+ Thalassemia in Northwestern Tanzania: Molecular and Hematological Insights From Newborn Screening.","authors":"Emmanuela E Ambrose, Benson R Kidenya, Luke R Smart, Alphaxard Manjurano","doi":"10.2147/JBM.S514273","DOIUrl":"10.2147/JBM.S514273","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to determine the prevalence of alpha+ thalassemia and its hematological indices in a newborn population in Mwanza city, North-western Tanzania.</p><p><strong>Patients and methods: </strong>A cross-sectional study screened 803 newborns for alpha+ thalassemia that extracted DNA from dried blood spots using the Qiagen Mini Kit then analysed by multiplex PCR. Demographic data, anemia-related clinical information, and CBC parameters were collected at birth. Prevalence was determined by the proportion of newborns with the alpha+ thalassemia deletion. Fisher's Exact test assessed differences in demographic and clinical variables, while Student's t-tests and ANOVA evaluated hematological parameters. A P-value < 0.05 was considered statistically significant.</p><p><strong>Results: </strong>Alpha thalassemia was detected in 49.6% (398/803) of neonates, with 38.6% heterozygous and 11.0% homozygous deletions. Significant differences in erythrocyte indices were observed across groups. Hemoglobin (Hb) levels were lower in heterozygous (_α/αα) and homozygous (_α/_α) newborns (16.42±3.62 g/dl and 16.04±3.37 g/dl, respectively) compared to the αα/αα group (17.03±3.35 g/dl, p < 0.05). Mean Corpuscular Volume (MCV) was reduced in heterozygous (_α/αα) and homozygous (_α/_α) groups (99.23±9.12 μm³ and 94.75±9.88 μm³, respectively) compared to αα/αα (102.41±9.56 μm³, p < 0.0001). Mean Corpuscular Hemoglobin (MCH) followed a similar pattern, being lowest in the homozygous group (p ≤ 0.0001). Red Cell Distribution Width (RDW) was higher in homozygous (_α/_α) newborns (10.03±1.22) compared to heterozygous (_α/αα) (9.57±0.79, p < 0.001). Leucocyte counts were significantly higher in heterozygous (_α/αα) newborns (13.91±12.14) compared to homozygous (_α/_α) (12.60±7.91) and αα/αα groups (11.26±9.76, p = 0.001).</p><p><strong>Conclusion: </strong>Alpha+ thalassemia is highly prevalent in North-western Tanzania and significantly affects blood indices. Neonatal screening is an effective tool for identifying affected children, especially in settings with high prevalence of a trait and low awareness of genetic inheritance.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"16 ","pages":"241-250"},"PeriodicalIF":2.1,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12087605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Matching-Adjusted Indirect Comparison of Elranatamab versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma: Updated Results.","authors":"Isha Mol, Yannan Hu, Thomas W LeBlanc, Joseph C Cappelleri, Haitao Chu, Guido Nador, Didem Aydin, Isabel Perez Cruz, Patrick Hlavacek","doi":"10.2147/JBM.S507550","DOIUrl":"10.2147/JBM.S507550","url":null,"abstract":"<p><strong>Background: </strong>Due to the absence of a head-to-head trial directly comparing elranatamab and teclistamab in triple-class exposed/refractory multiple myeloma (TCE/R MM), a matching-adjusted indirect treatment comparison (MAIC) was previously conducted. The aim of the current study was to update this prior MAIC with more mature clinical data from both trials.</p><p><strong>Methods: </strong>The approach of the MAIC remained consistent with the previous study, with the exception of more mature data (28.4 months and 30.4 months of follow-up for elranatamab from MagnetisMM-3 (NCT04649359) and teclistamab from MajesTEC-1 (NCT03145181, NCT04557098), respectively). Individual patient-level data from MagnetisMM-3 (N = 116) were reweighted to match published aggregated data from MajesTEC-1. Variables included for adjustment were age (≥75 years), sex (for OS only), median time since diagnosis, International Staging System disease stage, high-risk cytogenetics, extramedullary disease, number of prior lines of therapy, Eastern Cooperative Oncology Group performance status, and penta-exposed/refractory status. An unanchored MAIC was conducted based on the National Institute for Health and Care Excellence Decision Support Unit 18 example code. A sensitivity analysis was conducted in which missing baseline characteristics data were imputed for elranatamab.</p><p><strong>Results: </strong>In the base-case analysis, elranatamab was associated with significantly longer PFS (hazard ratio [HR] 0.55 [95% confidence intervals (CI): 0.37, 0.81], p < 0.05), OS (HR [95% CI]: 0.60 [0.40, 0.91], p < 0.05, and DoR 0.56 [0.31, 0.99] p < 0.05) compared with teclistamab. Results were largely consistent in the sensitivity analysis, except that the differences in OS were non-significant. A subgroup analysis of patients with a complete response or better was consistent with the base case.</p><p><strong>Conclusion: </strong>The results of this updated MAIC of elranatamab and teclistamab in TCE/R MM support the findings of the previous MAIC over a longer-term follow-up, now indicating significantly improved PFS, OS, and DoR with elranatamab versus teclistamab.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"16 ","pages":"233-239"},"PeriodicalIF":2.1,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics and Prognostic Value of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma Patients in China.","authors":"Chuanying Geng, Guangzhong Yang, Huixing Zhou, Zhiyao Zhang, Yuan Jian, Wenming Chen, Yanchen Li","doi":"10.2147/JBM.S514863","DOIUrl":"10.2147/JBM.S514863","url":null,"abstract":"<p><strong>Background: </strong>Newly diagnosed multiple myeloma (MM) patients with circulating plasma cells (CPC) had worse prognosis, and it was important to investigate the prognostic value of CPC for newly diagnosed MM.</p><p><strong>Methods: </strong>We retrospectively enrolled 718 patients with newly diagnosed MM and used propensity score matching to reduce the effect of different distributions of prognostic factors on the outcome.</p><p><strong>Results: </strong>We totally analyzed 718 patients included 103 (14.3%) patients with CPC and 615 (85.7%) patients without CPC. Median overall survival (OS) (35.1 months vs 57.4 months, p <0.001) and progression-free survival (PFS) (17.2 months vs 25.8 months, p =0.002) were significantly shorter in patients with CPC compared with that of patients without CPC. Univariate Cox proportional hazards regression analysis showed that CPC was associated with shorter OS (HR=1.740, 95% CI: 1.293-2.342, p<0.001) and PFS (HR=1.486, 95% CI: 1.149-1.921, p=0.003). However, it was showed that CPC was not an independent poor prognostic factor for OS (p=0.243) and PFS (p=0.228) in multivariable analyses. In the propensity score matching analysis, patients with CPC had similar OS (p=0.309) and PFS (p=0.686) to patients without CPC.</p><p><strong>Conclusion: </strong>Our study suggested that newly diagnosed MM patients with CPC had poor outcome, but CPC was not an independent poor prognostic factor for patients with newly diagnosed MM.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"16 ","pages":"221-231"},"PeriodicalIF":2.1,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Cost-Effectiveness of Low-Dose vs Standard Dose Prophylaxis for Hemophilia in Indonesia: A Systematic Review.","authors":"Pradana Zaky Romadhon, Kamila Auliya, Made Oka Heryana, Ajeng Ayu Erawati, Bagus Aulia Mahdi, Satriyo Dwi Suryantoro, Aditea Etnawati Putri, Narazah Mohd Yusoff","doi":"10.2147/JBM.S511906","DOIUrl":"https://doi.org/10.2147/JBM.S511906","url":null,"abstract":"<p><p>Studies on high-dose prophylaxis therapy using Factor VIII show promising decrease in the Annual Bleeding Rates (ABR) in hemophilia patients. However, the greater dose and frequency raise concerns on cost considerations and adherence of the patients, especially in several countries where resources are limited. Other data has proven that the low dose prophylaxis is also promising regarding the decrease of ABR. The purpose of this systematic review is to conduct a comprehensive analysis of the lower dosage formulation used for prophylaxis in hemophilia. A PubMed and Embase database search was performed based on articles that met the following criteria: written in English language and published within the last 10 years. Consequently, the following key terms were used in combination: 'high dose', 'low dose', 'recombinant', 'prophylaxis', and 'hemophilia' in different combinations. 19 articles were included for this review. 10 of the investigated papers demonstrated decrease in ABR, functional improvement of affected joints, alleviation of pain, and a better quality of life in hemophilia patients. Low dose prophylaxis has proven to significantly improve symptoms, lower ABR and preserve joint and bone health compared to episodic or on-demand treatment. Furthermore, low dose prophylaxis (LDP) was also observed to be cost-effective and more convenient in certain countries, especially in south-east Asia where resources are limited. Overall, low dose prophylaxis appears to be non-inferior in improving the overall Quality of Life in people with hemophilia, and therefore could be a beneficial alternative in countries of the south east Asian region.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"16 ","pages":"205-220"},"PeriodicalIF":2.1,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12056522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144019614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Survival Following Cladribine Containing Pretransplant Regimen for Autologous Hematopoietic Stem Cell Transplantation in Disseminated Interdigitating Dendritic Cell Sarcoma: A Case Report and Literature Review.","authors":"Pan Zhou, Lu Nie, Rongjun Ma, Xiaoyan Wang, Guangyin Wu, Zunmin Zhu, Xiaoli Yuan","doi":"10.2147/JBM.S515776","DOIUrl":"https://doi.org/10.2147/JBM.S515776","url":null,"abstract":"<p><p>Interdigitating dendritic cell sarcoma (IDCS) is an exceedingly rare hematological neoplasm arising from dendritic cells that presents significant diagnostic and therapeutic challenges, particularly in cases of disseminated disease. Here, a 33-year-old woman presented with discomfort of the left pharynx accompanied by nasopharyngeal and cervical mass for 3 months. The histopathology confirmed the diagnosis of IDCS as the neoplastic cells were spindle or ovoid in shape, forming fascicles or whorls, and were positive for S-100, vimentin and CD163 but negative for CD21, CD23, CD35 and CD1a. The patient underwent autologous hematopoietic stem cell transplantation (auto-HSCT) after achieving partial remission (PR) from six courses of chemotherapy based on the ABVD regimen and one cycle of radiotherapy. Encouragingly, the mass disappeared after cladribine containing regimen pretreated auto-HSCT and the patient has been in complete remission (CR) state for over 5 years. Therefore, the long survival of this patient might suggest that ABVD regimen with a sequential cladribine-containing preparative regimen prior to auto-HSCT may improve the prognosis of disseminated IDCS. However, this represents only a single-case experience, and further studies with larger sample sizes are required for validation.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"16 ","pages":"197-203"},"PeriodicalIF":2.1,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Attitude, Knowledge, and Willingness to Donate Blood Among Health Professional Students in Northern Uganda.","authors":"Peninah Nannono, Brenda Nakitto, Ivaan Pitua, Joseph Baruch Baluku, Daniel S Ebbs, Felix Bongomin","doi":"10.2147/JBM.S521698","DOIUrl":"https://doi.org/10.2147/JBM.S521698","url":null,"abstract":"<p><strong>Purpose: </strong>Blood transfusion is an essential component of healthcare systems, and blood donors play a critical role in saving lives and enhancing the well-being of others. This study explored blood donation practices among health profession students in northern Uganda.</p><p><strong>Participants and methods: </strong>We conducted an institutional-based, cross-sectional study with a quantitative approach from November 2023 to July 2024 across five healthcare institutions in Gulu. Attitude toward blood donation was assessed with seven questions, each scored from 0 (negative) to 2 (positive), yielding a total score per participant ranging from 0 to 28. The mean of these total scores across all 408 participants was calculated, with a mean total score of ≥5.0 indicating a positive group attitude, reflecting moderate favorability on average. Knowledge of blood donation practices was evaluated with 16 questions, each scored from 0 (incorrect) to 4 (fully correct), yielding a total score per participant ranging from 0 to 64. The mean of these total scores across all 408 participants was computed, with a mean total score of ≥12.0 signifying adequate group knowledge, representing a basic proficiency level. Willingness to donate blood was determined by a single question, with a \"YES\" response indicating willingness. Data were cleaned and analyzed using STATA 18.0, with descriptive statistics presented in tables. This study was approved by the Gulu University Research and Ethics Committee (GUREC-2023-619) on 11/11/2023.</p><p><strong>Results: </strong>A total of 408 participants were recruited, with a median age of 23 years (IQR: 21-24). Half of the participants identified as male, comprising 56.4% (n=230). Most participants demonstrated adequate knowledge about blood donation 73% (n=298). The overall positive attitude towards blood donation was 93.6% (n=382). Nearly all participants considered donating blood (99.0%, n=404), and 83.8% (n=342) expressed a willingness to donate blood in the future. However, only 48.8% (n=199) of respondents reported having donated blood in the past.</p><p><strong>Conclusion: </strong>While health profession students in northern Uganda exhibit adequate knowledge and positive attitudes towards blood donation, actual blood donation practices remain suboptimal. These findings highlight the need for interventions to translate knowledge and attitudes into consistent donation practices among this population.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"16 ","pages":"187-195"},"PeriodicalIF":2.1,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12012627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144002117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}